HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Johnson, S R Articles by Tattersfield, A E Search for Related Content PubMed PubMed Citation Articles by Johnson, S R Articles by Tattersfield, A E Topic Collections Relevant Article

Survival and disease progression in UK patients with lymphangioleiomyomatosis

¹ Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, UK
² Division of Respiratory Medicine, University of Nottingham, Nottingham, UK

Correspondence to:
Correspondence to:
Dr S R Johnson
Division of Therapeutics and Molecular Medicine, Queens Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK; simon.johnson{at}nottingham.ac.uk

Background: Lymphangioleiomyomatosis (LAM) is a rare and progressive disease of young women with no effective treatment. Previous estimates of 10 year survival, based mostly on case series or patients from tertiary centres, have ranged from 40% to 79%; no data are available on the progression of respiratory disability. In order to provide data for patients and for planning intervention studies, we have looked at the time course of LAM using a national cohort.

Methods: Time to death, time to MRC dyspnoea grades 2–5, and need for oxygen in patients on the UK LAM database were analysed using Kaplan-Meier analysis and Cox regression.

Results: Fifty seven of 72 patients responded with a median duration of follow up of 12.6 years (range 2.3–37) from the onset of symptoms. Ten year survival was 91% from onset of symptoms but varied widely with 11 patients alive after 20 years. Median time to MRC grade 3 dyspnoea (breathless walking on the flat) was 9.3 years (95% CI 5.1 to 13.4) from onset of symptoms.

Conclusions: Survival from LAM appears to be better than that reported in early studies. These data should be helpful for patients and for planning clinical trials.

Keywords: lymphangioleiomyomatosis; survival; MRC dyspnoea scale; Kaplan-Meier analysis

Relevant Article

Airwaves

Wisia Wedzicha
Thorax 2004 59: 729. [Extract] [Full Text] [PDF]

This article has been cited by other articles:

				F. X. McCormack Lymphangioleiomyomatosis: A Clinical Update Chest, February 1, 2008; 133(2): 507 - 516. [Abstract] [Full Text] [PDF]

				S. R. Johnson Lymphangioleiomyomatosis. Eur. Respir. J., May 1, 2006; 27(5): 1056 - 1065. [Abstract] [Full Text] [PDF]

				A Jaffe Orphan lung diseases in childhood: still unadopted? Thorax, November 1, 2005; 60(11): 892 - 894. [Full Text] [PDF]

				J. L. Black, Q. Ge, S. Boustany, P. R. A. Johnson, M. H. Poniris, A. R. Glanville, B. G. G. Oliver, L. M. Moir, and J. K. Burgess In vitro studies of lymphangioleiomyomatosis Eur. Respir. J., October 1, 2005; 26(4): 569 - 576. [Abstract] [Full Text] [PDF]

				C. S. H. Ng, S. Wan, T. W. Lee, and A. P. C. Yim Cystic lesions of the lung: a forgotten menace Eur. Respir. J., October 1, 2005; 26(4): 748 - 749. [Full Text] [PDF]

				G. F. Abbott, M. L. Rosado-de-Christenson, A. A. Frazier, T. J. Franks, R. D. Pugatch, and J. R. Galvin From the Archives of the AFIP: Lymphangioleiomyomatosis: Radiologic-Pathologic Correlation RadioGraphics, May 1, 2005; 25(3): 803 - 828. [Abstract] [Full Text] [PDF]